ReviewFrontiers in medicine2026
Gestational hypercalcemia: a narrative review of literature.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: We aim to perform a narrative literature review of gestational hypercalcemia including calcium homeostasis in pregnancy. Additionally, we demonstrate the diagnostic and therapeutic challenges and pitfalls of gestational hypercalcemia. Methods: Literature review. Results: Gestational hypercalcemia is a rare yet life-threatening condition. The presentation of gestational hypercalcemia is nonspecific and mimics common pregnancy-related symptoms contributing to missed or late diagnosis. Common morbidities include nephrolithiasis and pancreatitis in the mother and adverse obstetrical outcomes such as fetal loss, fetal growth restriction, preeclampsia and preterm delivery. Severe cases of neonatal hypocalcemia due to fetal hypoparathyroidism may lead to tetany and even death. Despite these risks, only few guidelines in the management of gestational hypercalcemia exist. Causes of gestational hypercalcemia can be divided into parathyroid hormone (PTH)-dependent versus PTH-independent disorders. PTH-dependent etiologies display increased or inappropriately high PTH levels; primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcemia (FHH) are the main contributors. PTH-independent disorders include pseudohyperparathyroidism, malignancy, and excessive calcium intake including calcium alkali syndrome. Granulomatous diseases, cytochrome P450 family 24 subfamily A member 1 (CYP24A1) mutations, and excessive calcium intake are the main contributors. In the presence of maternal hypercalcemia, hypercalciuria is a common laboratory finding. Extended laboratory work-up is the most useful paraclinical examination in gestational hypercalcemia of unknown cause. Only FHH is usually associated with low urinary calcium excretion. Marked sarcoidosis-associated hypercalciuria in pregnancy is attributed to the increase in both renal and ectopic calcitriol production, due to pregnancy and sarcoid granulomas, respectively. Conclusion: More than 90% of cases of gestational hypercalcemia are caused by PHPT, which in turn is mostly caused (over 80%) by a single parathyroid adenoma. However, we have to consider a number of other possible etiologies. We need to consider the increased risk of maternal, neonatal, and fetal complications. The review illustrates the various clinical presentation and complex therapeutic management of gestational hypercalcemia, necessitating an interdisciplinary approach to the mother and child.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.